CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising ...

CG Oncology, Inc. (CGON) closed the last trading session at $29.61, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated ...

CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock. Discover Fast ...

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene ...

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) shares were down 6.9% during mid-day trading on Monday .The stock traded as low as $27.84 and last traded at $27.98. Approximately 108,925 ...

CG Oncology has a 1-year low of $25.77 and a 1-year high of $50.23. Get CG Oncology alerts: CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings results on Tuesday ...

The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene is differentiated by its “superior” efficacy and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...